The effect of sacubitril/valsartan on urinary C-peptide excretion and endogenous insulin secretory capacity in a patient with type 2 diabetes: a case report
Abstract Background The evaluation of endogenous insulin secretory capacity is important in the selection of diabetes treatment. C-peptide, which is secreted in equivalent amounts as insulin, is a versatile test for this evaluation. Urinary C-peptide is widely used because it is less invasive. Sacub...
Saved in:
| Main Authors: | Shun Onodera, Masashi Miyamae, Issei Higuchi, Shunsuke Nashimoto, Akinobu Nakamura, Mitsuru Sugawara, Yoh Takekuma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Journal of Pharmaceutical Health Care and Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40780-025-00472-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
by: Zh. D. Kobalava, et al.
Published: (2017-07-01) -
Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan
by: José-Manuel Rubio-Campal, et al.
Published: (2025-06-01) -
Utility of the random C-peptide and random C-peptide index at diagnosis as a predictor of disease type and long-term insulin secretory capacity in children with diabetes mellitus
by: Keita Numasawa, et al.
Published: (2025-06-01) -
Association of angiotensinogen and angiotensin II receptor type I polymorphisms with biomarkers of carbohydrate and lipid metabolism in Dagestan residents with type 2 diabetes and hypertension
by: M. Z. Saidov, et al.
Published: (2021-11-01) -
Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
by: Narainrit Karuna, et al.
Published: (2025-05-01)